940P cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Pal S, Bajorin D, Hoffman-Censits J, Quinn D, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Soifer H, Li G, Dambkowski C, Moran S, Wang H, Daneshmand S, Rosenberg J. 940P cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC). Annals Of Oncology 2019, 30: v377-v378. DOI: 10.1093/annonc/mdz249.037.Peer-Reviewed Original ResearchMetastatic urothelial cancerGenentech/RocheOverall response rateBristol-Myers SquibbComprehensive genomic profilingProgressive diseaseEMD SeronoFGFR3 mutationsTumor tissueSeattle GeneticsAstellas PharmaFGFR3 alterationsClovis OncologyRoche/GenentechGenomic alterationsPrior platinum-based chemotherapyBest overall response rateDisease control ratePhase Ib trialPlatinum-based chemotherapyTime of screeningMutations/fusionsBackground Previous studiesCancer Research NetworkWarrants further studyInfigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
Dizman N, Rosenberg J, Hoffman-Censits J, Quinn D, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Soifer H, Li G, Dambkowski C, Moran S, Ye Y, Daneshmand S, Bajorin D, Pal S. Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results. Journal Of Clinical Oncology 2019, 37: 4510-4510. DOI: 10.1200/jco.2019.37.15_suppl.4510.Peer-Reviewed Original ResearchUpper tract UCMetastatic urothelial carcinomaUrothelial carcinomaPrior platinum-based chemotherapyUpper tract urothelial carcinomaDisease control ratePrior antineoplastic therapyPlatinum-based chemotherapyOverall response rateComprehensive genomic profilingDistinct biologic characteristicsFGFR3-TACC3 fusionMutations/fusionsCell-free DNA resultsGood responseEligible ptsS249C mutationAdjuvant studiesFGFR3 alterationsControl rateAntineoplastic therapyDistinct biologyBiologic characteristicsResponse rateInfigratinib